TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Says Anthropic No Longer Seen as National Security Threat 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
BEIJING, Feb. 2, 2016 -- BeiGene, Ltd. ("BeiGene" or "the Company"), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the pricing of its initial public offering of 6,600,000 American Depositary Shares ("ADSs"), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS, before underwriting discounts. In addition, BeiGene has granted the underwriters a 30-day option to purchase up to an additional 990,000 ADSs at the initial public offering price. All of the ADSs are being offered by BeiGene. The ADSs are expected to begin trading on The NASDAQ Global Select Market on February 3, 2016 under the ticker symbol "BGNE." The offering is expected to close on February 8, 2016, subject to customary closing conditions.
Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 2, 2016. The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
CONTACT: Media/Investor Contact:
Xin Huang
US: +1 917-617-4653
China: +86 185-1406-3050
[email protected]
